Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted therapies such as monoclonal antibodies and tyrosine kinase inhibitors. The use of targeted therapies has significantly improved survival outcomes for patients with ALL and has become a mainstay of frontline treatment. Since the FDA approval of blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, clinical trials have been increasingly investigating combination regimens with these targeted agents with the goal of optimizing their use and reducing the need for cytotoxic therapies.
In today’s podcast, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Daniel W. Lee, MD, of the University of Virginia, Charlottesville, VA, Nicholas Short, MD, of the MD Anderson Cancer Center, Houston, TX, and Robin Foà, MD, of the Sapienza University of Rome, Rome, Italy, talk on the latest clinical updates on the use of targeted therapies for the treatment of ALL, as presented at the European Hematology Association (EHA) Congress 2021.
The post EHA 2021: targeted therapies for ALL appeared first on VJHemOnc.
